November 16-17 | Hyatt Regency Boston
Sample operations sits at the center of every clinical trial, yet the data needed to manage it is often scattered across labs, sites, systems, and teams. As studies become more complex, it becomes increasingly challenging to maintain visibility, reconcile discrepancies, and identify risk before it impacts timelines or data quality.
QuartzBio is proud to sponsor the inaugural Biomarker Operations & Biospecimen Management Summit, bringing together 120+ senior leaders from biopharmas, CROs, central labs, and biobanks to discuss the operational realities of managing samples at scale.
At the QuartzBio booth, see how Sample Intelligence helps teams identify collection compliance issues, detect data quality problems, and monitor vendor performance, supporting earlier action on risks to study execution.
Join Us at the Conference
Panel Discussion:
“Choosing Build vs. Buy for Sample Tracking Technology & Making Either Work at Scale”
November 16
1:15 PM – 1:45 PM
Moderated by: Melinda Pautsch, Chief Commercial Officer, QuartzBio
Panelists:
- Narasimha Marella, Eli Lilly & Co.
- Medha Kamat, Johnson & Johnson
- Alyssa Masciarelli, Bicycle Therapeutics plc
- Jonathan Saunders, Moderna
Join us at this panel discussion to hear from operations leaders who’ve lived both sides of this decision to unpack:
- What actually drives the build-vs-buy decision (hint: it’s rarely just cost)
- How to scale a chosen approach across global, multi-site, or multi-vendor trials
- The hidden failure points teams don’t see coming, in either path
- Practical criteria for evaluating the risks in your current systems
Visit the QuartzBio Booth
See a live demonstration of QuartzBio Sample Intelligence focused on identifying sample operations issues early and giving teams the visibility they need to act.
Bring your questions about managing samples across sites, labs, and vendors, and discuss your workflow with the QuartzBio team.
Learn how your team can:
- Identify missed and out-of-protocol collections early, helping inform site retraining or updates to collection instructions
- Flag potential data quality issues upon receipt of data and streamline query management
- Investigate recurring data issues and address their root causes
- Monitor critical lab activity timelines against expectations to identify potential impacts on downstream sample analysis
Whether you work in biomarker operations, biospecimen management, translational research, or clinical operations, explore how earlier visibility can help your team strengthen sample oversight and reduce avoidable work.
